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Abstract 
Klinefelter syndrome (KS), the most frequent chromosomic abnormality in males, is 
associated with hypergonadotropic hypogonadism and an increased risk of cardiovascular diseases 
(CVD). The mechanisms involved in increasing risk of cardiovascular morbidity and mortality are 
not completely understood. Insulin resistance, metabolic syndrome, and type 2 diabetes are more 
frequently diagnosed in KS than in the general population; however, the contribution of 
hypogonadism to metabolic derangement is highly controversial. Whether this dangerous 
combination of risk factors fully explains the CVD burden of KS patients remains unclear. In 
addition, testosterone replacement therapy only exerts a marginal action on the CVD system. This 
review summaries the current understandings of the complex relationship between KS, metabolic 
syndrome and cardiovascular risk in order to plan future studies and improve current strategies to 
reduce mortality in this high-risk population. Since fat accumulation and distribution seem to play a 
relevant role in triggering metabolic abnormalities, an early diagnosis and a tailored intervention 
strategy with drugs aimed at targeting excessive visceral fat deposition appear necessary in patients 
with KS.  
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Introduction 
Klinefelter syndrome (KS) is an aneuploidy characterized by a supernumerary X 
chromosome and hypergonadotropic hypogonadism [1]. The estimated prevalence of 1 case per 660 
newborns, increasing to 3–4% among infertile men and 10–12% in azoospermic men, makes KS the 
most common abnormality of sex chromosomes [2-4]. Clinical features of the syndrome vary 
broadly [5-9], but the hallmark of KS remains infertility [5] with most of cases remaining 
undiagnosed until the attempt to conceive [10]. While about 85% of KS is due to one single 
additional X chromosome (47,XXY), the remaining 15% displays multiple aneuploidies 
(48,XXXY; 48,XXYY; 49,XXXXY) causing development of a much more complex phenotype 
[11]. This includes mental retardation that is no longer considered a feature of classical KS [12]. 
For this reason, aneuploidies with more than 47 chromosomes should be considered a distinct 
condition [5,11]. 
Compared to the general population, patients with KS show higher all-cause and 
cardiovascular disease (CVD) mortality [13-17]. Data from recent large registry-based studies 
reported a significant increase in mortality risk by 40% (hazard ratio (HR) for all-cause mortality = 
1.40; HR cardiovascular mortality = 1.41) [14] with a standardized mortality ratio (SMR) of 1.5 
[15], corresponding to a significantly reduced median survival of 2.1 years.  Patients with KS are 
more frequently insulin resistant, obese and prone to develop type 2 diabetes mellitus (T2D) 
[18,19], a condition considered a CVD equivalent. The onset of T2D in patients with KS is a 
turning point in worsening of the CVD risk profile. With this in mind, we explored and reviewed 
the relationship between KS and metabolic abnormalities, focusing on diabetes mellitus and its 
implications on the increased CVD mortality observed in KS patients.  
 
Insulin-resistance and metabolic syndrome in Klinefelter syndrome 
According to the National Cholesterol Education Program - Adult Treatment Panel III 
(NCEP- ATP III) criteria [20], metabolic syndrome (MS) clusters multiple CVD risk factors. In 
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2005, the International Diabetes Federation (IDF) reviewed these criteria which lead to an increased 
estimated prevalence of MS [21]. These criteria have now been reconciled in a joint interim 
statement to more precisely characterize MS [22]. Furthermore, a definition of pediatric MS, 
designed to be closely analogous to ATP III, was described by de Ferranti et al. in 2004 [23].    
 As summarized in Table I, the prevalence of MS in patients with KS appears higher than in 
the general population, with data suggesting a 4-fold higher prevalence of MS in untreated KS than 
controls (46% vs 10%) [24]. In the same study, patients with KS presented with insulin resistance 
(IR - measured by the HOMA index), low androgens and low HDL cholesterol concentrations. KS 
was consistently associated with increased total body fat, however surprisingly, testosterone 
replacement therapy (TRT) did not modify fat tissue distribution or insulin sensitivity (IS) (Table I 
and Fig.1). Similar findings in respect to lipid and testosterone levels and MS were described in a 
subsequent study [25]. More than one third of patients with KS were identified as IR when tested by 
the euglycemic hyperinsulinemic clamp [26]. In this elegant study, serum testosterone levels were 
independently associated with insulin-mediated whole body glucose uptake, suggesting 
hypogonadism might be responsible for IR in KS patients [26].  In a smaller study, Pei and 
colleagues confirmed that IR, measured by insulin area under the curve (AUC) during a 75-gr oral 
glucose load and insulin suppression test, was constantly elevated in patients with KS [27]. 
Interestingly, plasma glucose at the steady state was inversely correlated to testosterone levels, 
again pointing toward a role for androgens in the IR of KS. In a study performed by ourselves, we 
described a prevalence of 49% for MS in 69 untreated KS patients, compared to 10% among 
controls [28]. In the 48 patients prescribed TRT, the prevalence of MS during the 3-year follow-up 
period was unaltered and remained higher than that observed in a group of 21 men with 
hypogonadotropic hypogonadism treated with testosterone [28]. These data indicate that KS 
patients are more insulin resistant, have increased body fat and lower levels of HDL, and show an 
increased prevalence of MS when compared to a control population. Also, circulating testosterone 
appears related to IS, however, the effect of TRT does not reverse MS. In the general population 
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and in experimental models, a clear bidirectional relationship between testosterone and IS exists 
[29-31]. Low testosterone levels are associated with increased IR [31] and the onset of IR may 
influence testosterone levels [32,33] (Fig. 1). Treatment of hypogonadal men with testosterone 
improves metabolic risk factors and IR in some, but not all studies [34]. Compared to other types of 
hypogonadism, TRT has shown to not improve body fat distribution or IR in KS [24,28], suggesting 
either a possible“ hormonal resistance”, consistent with the accompanying elevated LH [10], an 
increased aromatization [35],  or alternatively, that the androgens are not involved in the metabolic 
impairment of KS.  The chromosomal abnormality may act through additional mechanisms in 
triggering IR, differential body fat distribution and MS (Fig. 1), despite inactivation of the extra X 
chromosome. From this point of view, the study of prepubertal adolescents with KS offers an 
important opportunity. Although they carry the chromosomal abnormality of the syndrome these 
patients have similar, prepubertal, circulating testosterone and gonadotropin plasma levels to age-
matched healthy controls. Therefore, the independent, non-hormonal, role of chromosomal 
abnormalities can be better ascertained at this age [10,36].  In a group of 89 boys between 4 and 12 
years, 30% had a waist circumference >90th percentile (vs 21% matched controls), 24% were 
insulin resistant and 7% had three age-matched criteria for the diagnosing MS [37].   In a more 
recent cohort of 93 pre-pubertal boys with KS [38], 80% had ≥1 feature of MS and 11% had ≥3 
features of MS. In the same cohort of patients, authors performed a 2-year double-blind placebo-
controlled trial of oral oxandrolone (Ox) [39]. This showed a modest improvement in some 
features of MS (systolic BP, fasting blood glucose, and triglycerides) and in body composition 
although, after adjusting for age and baseline measures, the only significant change was a 
reduction of triglycerides. In particular, these changes were more strongly associated within 
the subgroup of patients who remained prepubertal throughout the 2-year study. In addition, 
the treatment did result in bone age advancement and lowering of HDL cholesterol. Of note, 
total body fat, assessed by bioelectrical impedance analysis, was found higher in infants and 
adolescents with KS, independently of BMI, age, and testosterone concentration. Thus, KS patients 
 6 
 
seem to display an accumulation of truncal body fat and lower lean body mass (28). Iwatsuki et al. 
demonstrated that LH and FSH, but not testosterone, inversely correlate with BMI in KS but not in 
men without KS [40]. Aksglaede et al. comparing eighteen untreated and six testosterone-treated 
KS boys to a group of normal aged-matched controls, found an increased fat body mass, but normal 
lean body mass, in patients with KS [41]. Overall, these data suggest that an unfavorable metabolic 
profile is already present in children with KS, although testosterone levels are not different from 
their healthy peers.  
Bojesen et al. showed that in patients with KS, as for the general population, truncal body 
fat is associated with IR [22]. Interestingly, when metabolic data from patients with KS were 
adjusted for truncal body fat, the correlation with hypogonadism was lost, suggesting that the 
effects of androgens on IS was mediated by fat distribution. Recently, in a group of ten obese KS 
patients with T2D and erectile dysfunction (ED), the addition of metformin and liraglutide induced 
weight loss and improved erectile function in the patients in which TRT alone was insufficient to 
achieve serum T levels in the range of healthy men. Furthermore, the patients were able to reach 
glycemic targets and to lower weight, leading to a considerable improvement of ED [42].  
Recently, a prevalence of obesity in Korean men with KS of 42.6% was reported, with 
testosterone level as an independent risk factor for obesity and hyperglycemia [43]. On the other 
hand, obesity in KS is not just a bystander, since only KS patients with obesity have a high 
incidence of hyperglycemia, low testosterone level, and elevated LH and FSH levels [44]. 
A very intriguing relationship exists between KS, MS and the increased risk of 
thromboembolic disease [18,43,45,46]. MS is associated with a low-grade chronic inflammatory 
status. Recently in a cohort of 26 testosterone treated KS patients, serum levels of C-C motif 
chemokine ligand 2 (CCL2), the major chemokine released by the monocytes and macrophages and 
associated with IR, along with prevalence of MS (50%) and IR were higher than in controls. 
However, when the group of patients was divided according to the presence of MS, hormone 
concentrations, adiponectin, CCL2, and CXC motif chemokine 10 (CXCL10) levels were similar.  
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Therefore, the effects on CCL2 circulating plasma levels seen in KS were not mediated by MS or 
body fat distribution, rather to other putative mechanisms operating in KS itself. In fact, the 
observation that in patients with KS testosterone correlated positively with CCL2 contrasts with in 
vitro data where testosterone reduces the secretion of several cytokines and chemokines, including 
CCL2, from peripheral blood mononuclear cells [47]. Consistently, when adult men are acutely 
deprived of testosterone, CCL2 levels increase. These data suggest that a proinflammatory status in 
KS may also account for some dysfunction of Leydig cells [47,48] and that macrophage infiltration 
into an expanded adipose tissue might be involved in the development of MS in KS [49]. 
 
Diabetes mellitus in Klinefelter syndrome 
Type 1 diabetes mellitus (T1D) accounts for between 5 and 10% of all diabetes cases and is 
due to autoimmune destruction of the pancreatic beta-cells [50]. Autoimmunity is also frequent in 
KS. Interestingly, a recent study demonstrated that immunoreactivity directed against diabetes-
specific autoantigens was significantly increased in KS (8.2%) than matched controls, but the 
autoantibody endocrine profile of untreated and treated KS patients was not different [51]. Bojesen 
et al. [13] reported a 2.5-fold increased risk of T1D in KS when compared to the general 
population.  Since the first study evaluating the prevalence of T2D and KS performed by Langeron 
et al. in 1958 [52], many reports [53-66] have documented the association of KS with T2D (Table 
II). An abnormal oral glucose tolerance test can be detected in more than one third of KS patients 
[56], leading to the suggestion of considering KS a “prediabetes” [57]. The prevalence of overt 
diabetes in KS is estimated higher than 10% in various studies [59-65,67]. Interestingly, the 
prevalence of diabetes is increased also in parents of siblings with KS [61], suggesting a familiar 
cluster of the metabolic abnormalities. Of interest is the observation that the prevalence of diabetes 
is even higher (up to 57%) in patients with the more severe karyotypes (48, or 49 chromosomes), 
pointing to an additive role of the supernumerary X-chromosomes in the onset of T2D in KS [62]. 
Our group reported a prevalence of diabetes slightly higher than in the general population [28]. 
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Recently, Han et al found a prevalence of 26% of “prediabetes” and of 13% of diabetes in 375 
Korean KS patients. Despite no difference observed for the prevalence of diabetes between obese 
and non-obese KS patients, prediabetes was more frequent in the obese KS group [43].  
The course of diabetes in patients with KS has some peculiarities compared to the general 
population. In particular, KS patients develop the disease earlier in life (onset around 30 years) and 
with an associated BMI lower than what is usually observed in non-KS patients with T2D. Finally, 
insulin treatment appears less effective in achieving metabolic control [60], but compliance might 
be a confounding issue. As for MS, TRT does not halt the onset of diabetes in KS, nor changes its 
severity [45]. Data from large registry-based studies showed a HR of 2.21 for T1D and 3.71 for 
T2D in KS [13-17]. In a cohort of 781 Danish KS patients, a 60% increase in the risk of death due 
to T2D was reported [13]. However, such reported risk might well be underestimated, since T2D is 
not usually recorded as a primary cause of death. Swerdlow et al. extracted data from a cohort of 
4806 UK-based patients with KS diagnosed between 1959 and 2002 [15]. The authors calculated 
the SMR related to diabetes at 5.8 and showed that the contribution of diabetes as the cause of death 
in this population increased with age. In addition, no differences were found when the classic XXY 
karyotype was compared with other chorotypes or mosaic, although abnormal glucose tolerance 
was more frequently detected in classical KS [57].  
 The clinical response to TRT might be influenced by the polymorphism of the gene 
encoding for the androgen receptor on the X chromosome. A certain number of CAG repeats 
(CAGn) characterizes this gene and the number of CAGn is inversely associated with androgen 
sensitivity: the higher the CAGn, the lower the sensitivity to androgens, suggesting a possible role 
in the clinical response to testosterone therapy in KS [67].  Bojesen and collaborators, studying a 
group of 70 patients, supported the concept that CAGn polymorphism affects the phenotype of KS 
[68]. However, in this cohort, the CAGn repeats influenced height, arm span, total cholesterol, 
hemoglobin, and red blood cell count of KS patients, but not the response to TRT.  Although 
testosterone might potentially affect metabolism through several mechanisms [69-72], TRT in KS 
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does not seem directly affect glucose metabolism.  
 
Diagnostic and therapeutic perspectives  
Although KS patients are more insulin resistant and have an increased risk of developing 
MS and T2D, they are not listed among groups requiring a more frequent screening for metabolic 
impairment.  Since T2D severely impacts mortality in KS and current standards of TRT failed to 
prove effective in this respect, an open issue remains on how to prevent or treat diabetes in KS 
patients. Specifically, no information is available within current guidelines regarding a particular 
strategy to be used in the prevention of diabetes or its complication in this particular group of 
patients [73]. In contrast, it is suggested that in any individual older than 45 years and with a 
condition of IR, such as polycystic ovary syndrome, severe obesity or acanthosis nigricans, should 
be tested for diabetes. We propose to add KS as a condition requiring early screening, maybe even 
earlier than 45 years, given the early onset of T2D in KS patients. 
Counseling from an early age regarding a healthy diet and regular exercise is imperative for 
KS patients. As suggested by Davis et al [74],  a screening for dyslipidemia with a fasting lipid 
panel at age 9 to 11 years and after puberty is completed (or sooner if additional risk factors are 
present) could be a good strategy to recognize MS or its features as soon as possible. This 
assessment needs to be repeated after puberty, and it is necessary to consider KS patients at high-
risk of developing MS and T2D throughout their life.   
In KS patients with MS or prediabetes, a Diabetes Prevention Program (DPP) should be 
considered. DPP, consistent in lifestyle changes such as nutritional suggestions (e.g. reducing 
caloric intake and increasing consumption of food high in monounsaturated fats), and physical 
activity (exercise prescriptions designed to prevent diabetes are based on aerobic activity and may 
include resistance training) has provided the strongest evidence for diabetes prevention in the 
general population [75,76]. Moreover, the use of metformin was effective in reducing the risk of 
diabetes by one third in individuals at high-risk for the disease [76]. Although solid data regarding 
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patients with KS are lacking, the use of metformin in these patients might be equally effective.   
When a diagnosis of T2D has been made, lifestyle management exerts a pivotal role in 
diabetes care with the latest guidelines including diabetes self-management education and support 
(DSMES), medical nutrition therapy (MNT), physical activity intensification, smoking cessation 
counseling, and psychosocial care [77]. In particular, considering the associated neuropsychological 
and behavior disorders described in KS, the multidisciplinary management of this aspect is an 
important factor that needs to be considered in the management of T2D in KS. Considering the 
well-known cardiovascular alterations [18,28], before starting physical activity a cardiovascular 
assessment is required, as elsewhere described [18].       
No solid evidence is available for which drug is most appropriate for the treatment of 
diabetes or its complications in KS patients. However, given the fact that fat accumulation and 
distribution seems to plays a pivotal role in triggering metabolic abnormalities, drugs targeting body 
fat should be preferred.  Although few data are available on the effect of hypoglycemic agents in 
KS, some drugs appear to be preferential [42,62]. In particular, metformin and GLP-1 receptor 
agonists should be the preferred drugs to use in KS patients with diabetes. Finally, the few data 
available suggest that KS patients with diabetes are not easily controlled by insulin treatment [56], 
therefore prevention strategies should be aggressive to delay the use of insulin. Future research 
should directly address the issue to provide evidence regarding the best approach for patients with 
KS and diabetes. 
 
Conclusions 
KS is described by a vicious circle and network of complex interactions that establish health 
complications of patients (Figure 1). Chromosomal abnormalities, influence body composition, 
causing an increase in body fat (especially intra-abdominal fat), the onset of IR and a related 
deterioration of carbohydrate metabolism leading to diabetes, but also induce the reduction of 
androgen secretion. Furthermore, IR aggravates hypogonadism [33] via a direct effect to further 
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exaggerate the dysfunction of testosterone production by the Leydig cell [78]. In KS, TRT does not 
appear to change the prevalence of MS or to improve indices of IR, suggesting that more complex 
and unclear mechanisms sustain the link between KS and MS [40]. An early diagnosis and tailored 
intervention strategy seem mandatory in patients with KS, and should be aimed at targeting 
excessive visceral fat deposition. 
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Table I. Studies evaluating metabolic syndrome and insulin resistance in Klinefelter syndrome 
 
Author, year (ref) 
 
Pts Criteria used for 
diagnosis of IR or MS  
Findings Relationship with T   
A. Adult population 
A1.Insulin resistance 
    
Pei D, 1998 [27] 7 the total area under the 
curve (AUC) and the 
incremental AUC of serum 
insulin concentrations in 
response to a 75-g oral 
glucose load, and the 
insulin suppression test 
decreased insulin 
sensitivity and 
elevated fasting 
insulin in KS 
Plasma glucose inversely related to T 
levels 
Yesilova Z, 2005 [26] 13 hyperinsulinemic 
euglycemic clamp 
IR prevalence: 
39% 
T as an independent determinant of 
whole-body glucose disposal rate with 
hyperinsulinemic euglycemic clamp 
Bardsley MZ, 2011 [37] 89 HOMA 
 
IR prevalence: 
24% HOMA > 2.5 
9.3% had fasting 
insulin levels >20 
IU ⁄ mL 
- 
A2. Metabolic Syndrome     
Bojesen A, 2006  [24] 70 NCEP/ATP III criteria 
(all criteria for MS 
diagnosis were present 
except for BP) 
MS prevalence: 
47% in KS (46% 
in untreated KS vs 
49% in treated 
KS) vs 
10% in controls 
T therapy did not affect IR 
(IM T injections [20 pts], oral T 
undecanoate [14 pts], and mesterolon 
[1 pt]) 
 
Ishikawa T, 2008 [25] 60 revised NCEP/ATP III 
criteria in Japan 
(all criteria for MS 
diagnosis were present 
except for BP and FBG). 
MS prevalence 
34% in KS vs. 
22% in controls 
- 
Jiang-Feng M, 2012 [62] 39 IDF criteria MS prevalence: 
30.8% before T 
treatment, 38.5% 
after T treatment 
for a median 
duration of 4 
years in KS vs 
15% and 20% 
respectively 
before and after T 
therapy in 
controls 
body weight and BMI significantly 
increased during long-term T 
replacement Treatment 
(before 1993, 100 mg 
compound T was injected IM at an 
interval of 10 days; after 
1993, 250 mg T undecanoate was 
injected IM monthly) 
Pasquali D, 2013 [28] 69 NCEP/ATP III criteria 
(18 KS pts had increased 
waist circumference, 16 
had impaired fasting 
glucose, 3 had diabetes 
mellitus, 12 had elevated 
triglycerides, 13 had 
decreased HDL 
cholesterol, and 4 had high 
diastolic blood pressure) 
MS prevalence: 
49% in  KS (47% 
untreated vs 50% 
treated) vs 
10% in controls 
No effect of T therapy 
(1000 mg 
long-lasting IM T every 3 months ) 
B.Pediatric population 
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Bardsley MZ, 2011 [37] 89 
 adaptation of NCEP/ATP 
III for pediatric use  
65% of KS pts had 
decreased HDL levels, 
15% had elevated TG 
levels, and 49% had a WC 
>75 percentile. None had 
elevated BP or FBG. 
 
36% with ≥ 1 MS 
feature 
8%  with ≥ 3 MS 
feature 
 
- 
Davis S, 2016 [38] 93  
pre-
puber
tal 
adaptation of NCEP/ATP 
III for pediatric use 
80% with  ≥1 MS 
feature  
11% with  ≥3 MS 
features  
No relationship  
between T and MS  
Davis S, 2017 [39] 93  
pre-
puber
tal 
adaptation of NCEP/ATP 
III for pediatric use 
80% with  ≥1 MS 
feature  
11% with  ≥3 MS 
features 
T therapy had a modest improvement 
on features of MS and body 
composition, more expressed in the 
subgroup of patients who remained 
prepubertal throughout the study 
despite a decline in HDL and little 
bone age advancement. 
(Oral oxandrolone (Ox) 0.06 
mg/kg/die or placebo) 
 
T: Testosterone; MS: metabolic syndrome; KS: Klinefelter Syndrome; IR: Insulin-Resistance;   HOMA: homeostatic 
model assessment: BP; blood pressure, FBG, fasting blood glucose; WC, waist circumference; Pts: patients; IM: 
intramuscular. National Cholesterol Education Program - Adult Treatment Panel III (NCEP- ATP III) criteria [20]: 1) 
increased waist circumference (i.e. in Caucasian males >102 cm, in Japan males >85 cm females >88cm ); 2) high 
plasma triglycerides  (>150 mg/dl; 3) low HDL-cholesterol (<40  in men and <50 mg/dl in women); 4) elevated systolic 
or diastolic blood pressure (>135 or 85 mmHg, respectively); 5) impaired fasting glucose (>110 mg/dl). 3 or more of 
the criteria needed.  International Diabetes Federation (IDF) criteria [22]:  central obesity with waist circumference >90 
cm, plus any two of four additional factors include triglyceride >150mg/dL, highdensity lipoprotein (HDL)-cholesterol 
< 40 mg/dL (or treatment for dyslipidemia), systolic blood pressure >130 mm Hg or diastolic blood pressure >85 mm 
Hg (or treatment of previous hypertension), and fasting plasma glucose > 100 mg/dL (or previously diagnosed type 2 
diabetes).  Adaptation of NCEP/ATP III for pediatric use [23]: 1) central obesity with waist circumference >75th 
percentile for age and gender, 2) high plasma triglycerides  (>97 mg/dl; 3) low HDL-cholesterol (< 50 mg/dL, boys 
aged 15–19 years < 45 ); 4) elevated systolic or diastolic blood pressure (>90th percentile for age, gender, and height); 
5) impaired fasting glucose (>110 mg/dl).  
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Table II.  Diabetes Mellitus in Klinefelter Syndrome  
Author, year (ref) 
 
Patients T2D Prevalence Effect of T replacement therapy 
(type of T therapy)  
Forbes AP, 1963 [61]  41 15% - 
Nielsen J, 1966 [60] 25 32%  
Jackson IM, 1966 [58] 8 12% - 
Becker KL, 1966 [59] 50 10% - 
Zuppinger K, 1967 [63]  24 25%  
Nielsen J, 1969 [56] 31 39%: specifically 20.8% in patients with 
47,XXY karyotype, 100% with other 
karyotypes (4 patients with 46,XY/47,XXY 
chimera and 3 patients with 49,XXXXY) 
- 
Sagara MN, 1986 [64] - 3,9% - 
Takeushi Y, 1999 [53] Rev 
15%-50% in Western countries 
3.9%-4.1% in Japan - 
Ota K, 2002 [65] 895 6.5% No effect 
(type of T treatment not reported) 
Lichiardopol C, 2004 [66]  31 16% of KS have Prediabetes 
0% have T2D  
- 
Bojesen A, 2004 [14] 781 
HR: T1D 2.21: T2D 3.71. 
Mortality for DM 1.64 - 
Swerdlow AJ, 2005 [15]  4806 
T2D cause-specific MR: 7.07; 
SMR:5.8; HR: 1,6 - 
Bojesen, A 2006 [24]  70 
10% (9% in untreated KS vs 11% in treated 
KS) 
No effect 
(intramuscular T injections [20 pts], 
oral testosterone undecanoate [14 
pts], and mesterolon [1 pt]) 
Jiang-Feng M, 2012 [62] 39 20.5%; specifically 
12.5% in 47,XXY and  57.1% in pts with other 
atypical karyotypes (46XY/47XXY 
chimera and others). 
Body weight and BMI significantly 
increased during 
long-term TRT 
(before 1993, 100 mg 
compound T was injected IM at an 
interval of 10 days; after 
1993, 250 mg T undecanoate was 
injected IM monthly) 
Pasquali D, 2013 [28] 69 8% (9% in untreated KS and 6% in treated KS) No effect 
(1000 mg 
long-lasting intramuscular T every 3 
months) 
Han SJ, 2016 [43]  376 Prediabetes: 26%; specifically, 19.8% in non-
obese pts and 38% in obese patients (p <.05) 
T2D: 12.8%; specifically, 11.6% in non-obese 
pts and 14.3% in obese pts 
 
- 
 
Rev: review; T: Testosterone; T2D: type 2 Diabetes Mellitus; KS: Klinefelter Syndrome; T1D: type 1 
Diabetes Mellitus; MR: mortality ratio; SMR: standard mortality ratio; HR: Hazard Ratio: pts: patients 
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Figure legends. 
 
Fig1. Vicious circle and network of complex interactions in Klinefelter syndrome.  
Klinefelter Syndrome induces hypogonadism and influences body composition, causing an increase 
in body fat (especially intra-abdominal fat), inducing IR which, in turn, aggravates the 
hypogonadism via a direct effect on Leydig cell production of residual testosterone. However, 
testosterone therapy does not appear to change the prevalence of MS or T2D nor improve indices of 
IR. The mechanisms active in the general population (panel A) or in the patients with KS (panel B) 
are depicted. Green circles represent the general population. Blue circles represent KS patients. 
Green or blue arrows indicate mechanisms active in the general population or in KS patients, 
respectively. The arrows are in continuous or dashed format to indicate an action toward an increase 
or a decrease of the target parameter, respectively.  
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